Nephros
Ex-J&J CEO Weldon to walk with $143.5M in retirement | Personnel Moves
Outgoing Johnson & Johnson (NYSE:JNJ) CEO William Weldon will take home $143.5 million in retirement benefits when he walks in April.
The veteran J&J employee racked up more than $95 million in deferred compensation and $48.4 million in pension benefits over more than 40 years with the health care titan, according to an SEC filing.
GE Healthcare begins PMA process for 3D breast scanner | Regulatory Roundup
GE Healthcare (NYSE:GE) filed the first module of its pre-market approval application for the breast tomosynthesis option of its Senographe Essential system.
The health care giant said the first submission included a device description and non-clinical information, including "phantom testing," and detector performance evaluation. The system is intended as an add-on option for the Senographe Essential to produce 3D images for screening and diagnosis of breast cancer.
FDA approves first drug-eluting implant for chronic sinusitis | Regulatory Roundup
Intersect ENT Inc. announced a landmark win for its flagship Propel drug-eluting implant for treatment of chronic sinusitis.
The Palo Alto, Calif.-based company’s device claims to be the first of a new category of devices offering localized, controlled steroid delivery directly to sinus tissue.
Nephros corporate strategy update highlights CEO search
Therapeutic filtration company Nephros Inc. (OTC:NEPH) unveiled a new corporate strategy this week, highlighting the search for a new chief executive to replace acting CEO Dr. Paul Mieyal.
"Nephros’s board of directors thanks Dr. Mieyal for his continued stewardship of the company during this period," said board chairman James Scibetta. "The company believes it is now well positioned to attract top talent for its future growth."
Penis stimulation device touts landmark FDA clearance for erectile dysfunction | Regulatory Roundup
Reflexonic LLC landed FDA clearance for the first hand-held, non-pharmaceutical device intended to help men with moderate erectile dysfunction, poor maintenance and rigidity or spinal cord injuries achieve successful erection and ejaculation at home.
Viberect is the only device in the world that delivers targeted vibration applied to the top and bottom of the penis using medical pads that stimulate the pudendal and dorsal nerves.
The tool is indicated for use prior to sexual activity and claims to amplify subsequent orgasm and ejaculation.
Cambridge Heart’s Q1 sales slide on Cardiac Science buyout | Earnings Roundup
Cambridge Heart Inc. (OTC:CAMH) took a hit during the first quarter, as last year’s acquisition of partner Cardiac Science helped drive sales down 3.2 percent, even as it prepped an offering to raise enough cash to keep going after the end of this year.
Derma Sciences sales jump 16 percent | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
CardioDx drums up $57 million for genetic tests | Funding roundup
CardioDx Inc. raised $57.5 million from equity and options investments, according to its latest filing with the Securities & Exchange Commission.
The Palo Alto, Calif.-based genomics firm is developing tests based on gene expression analysis to measure patients’ risk for cardiovascular diseases.
The new financing, which is part of the $78.3 million the company is trying to raise, was supported by 17 unnamed investors, according to the SEC filing.
Retina Implant closes $18 million round | Funding roundup
Sub-retinal prosthesis developer Retina Implant AG raised $18 million in venture capital funding.
The company’s sub-retinal implant is comprised of a microchip that’s inserted into the eye to restore vision for people suffering from retinitis pigmentosa, a retinal degeneration disorder.
Online physician community Sermo drums up $5 million | Funding roundup
Here’s a roundup of the latest dealflow and investment news: